Welcome to our dedicated page for Calliditas Therapeutics Ab news (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics Ab stock.
Calliditas Therapeutics AB (CALT) is a clinical-stage biopharmaceutical leader developing innovative therapies for rare renal and hepatic diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships shaping the future of orphan disease treatment.
Access timely announcements covering critical developments in IgA nephropathy research, NOX enzyme inhibitor advancements, and global commercialization efforts. Our curated collection includes press releases on Phase 3 trial results, FDA/EMA regulatory reviews, and licensing agreements with international partners.
Key focus areas include updates on lead product Nefecon® in IgAN therapy, setanaxib trials for fibrotic diseases, and market expansion strategies. Bookmark this page to stay informed about Calliditas' progress in addressing unmet medical needs through targeted molecular therapies.
Calliditas Therapeutics (Nasdaq: CALT) announced that its partner, Everest Medicines, has launched Nefecon® in China. China has up to 5 million patients with IgA nephropathy (IgAN), a progressive autoimmune disease. IgAN accounts for 35% to 50% of primary glomerular diseases, with over 100,000 new cases yearly. The Phase 3 NefIgArd trial showed a 66% reduction in kidney function loss in Chinese patients treated with Nefecon, outperforming global results.
Nefecon received conditional approval from China’s National Medical Products Administration (NMPA) in November 2023 and has since been launched in Macau, Hong Kong, and Singapore. The drug is also under review in Taiwan and South Korea.
Calliditas Therapeutics AB (CALT) announced positive results from a Phase 2 trial of setanaxib in combination with pembrolizumab for head and neck cancer treatment. The trial demonstrated significant improvements in progression-free survival and overall survival compared to placebo, with a positive impact on tumor biology. The treatment was well-tolerated, showing an increase in CD8+ T-cells in tumor tissue, indicating enhanced immunological activity. The company plans to present more data at an upcoming R&D day in Stockholm.
FAQ
What is the current stock price of Calliditas Therapeutics Ab (CALT)?
What is the market cap of Calliditas Therapeutics Ab (CALT)?
